YK-029A
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for YK-029A, covering 2023-04-05 to 2023-04-05. Get the full timeline:
Most recent: Clinical Trial Update: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [Phase 3]